期刊
CELL
卷 138, 期 3, 页码 476-488出版社
CELL PRESS
DOI: 10.1016/j.cell.2009.05.036
关键词
-
资金
- NIH [DK076729, P50 HL083762, R37 DK34388, P41 RR00954, HL089301]
- Clinical Nutrition Research Unit [DK56341]
- Diabetes Research and Training Center [DK20579]
- Betty Van Andel Foundation
- American Diabetes Association [1-07-JF-12]
The nuclear receptor PPAR alpha is activated by drugs to treat human disorders of lipid metabolism. Its endogenous ligand is unknown. PPAR alpha-dependent gene expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involved in generation of a PPAR alpha ligand. Here we demonstrate the FAS-dependent presence of a phospholipid bound to PPAR alpha isolated from mouse liver. Binding was increased under conditions that induce FAS activity and displaced by systemic injection of a PPAR alpha agonist. Mass spectrometry identified the species as 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Knockdown of Cept1, required for phosphatidylcholine synthesis, suppressed PPAR alpha-dependent gene expression. Interaction of 16:0/18:1-GPC with the PPAR alpha ligand-binding domain and coactivator peptide motifs was comparable to PPAR alpha agonists, but interactions with PPAR delta were weak and none were detected with PPAR gamma. Portal vein infusion of 16:0/18:1-GPC induced PPAR alpha-dependent gene expression and decreased hepatic steatosis. These data suggest that 16:0/18:1-GPC is a physiologically relevant endogenous PPAR alpha ligand.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据